Watch this video presentation by InMed’s CEO, Eric A. Adams, as he shares data on the unique pharmacological effects of INM-901, a drug candidate for the treatment of Alzheimer’s disease.
In the video, Eric Adams talks about the different pathological factors that lead to the development and progression of Alzheimer’s disease and how preclinical studies of INM-901 indicate how this small molecule drug candidate may address multiple mechanisms related to this disease.
This video presentation of INM-901 covers:
- Alzheimer’s disease prevalence and impact
- Alzheimer’s disease pathology
- Potential mechanisms of INM-901
- The endocannabinoid system and INM-901’s receptor interactions
- Preclinical results of INM-901 in well-recognized preclinical models of Alzheimer’s disease
- InMed’s preclinical results in studies related to neuroprotection in amyloid-beta toxicity study, neuritogenesis and Alzheimer’s disease behavioral tests
- mRNA analysis of INM-901 studies
- Next steps for the INM-901 program
